Search results
Showing 1 to 15 of 19 results for dopamine
This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing information and support, and palliative care.
This quality standard covers the management of Parkinson’s disease in adults. It does not include treatment of parkinsonism not caused by Parkinson’s disease. It describes high-quality care in priority areas for improvement.
View quality statements for QS164Show all sections
Sections for QS164
- Quality statements
- Quality statement 1: Point of contact with specialist services
- Quality statement 2: Information about impulse control disorders
- Quality statement 3: Referral to physiotherapy, occupational therapy or speech and language therapy
- Quality statement 4: Levodopa in hospital or a care home
- Quality statement 5: Access to clozapine for treating hallucinations and delusions
- About this quality standard
Question Dopamine: In people with acute heart failure, congestion and worsening renal function, does the addition of low‑dose...
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)
Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.
Evidence-based recommendations on MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson’s. This involves using ultrasound to destroy tissue in the thalamus.
View recommendations for IPG796Show all sections
MRI-guided focused ultrasound subthalamotomy for treating Parkinson's (IPG797)
Evidence-based recommendations on MRI-guided focused ultrasound subthalamotomy for treating Parkinson’s. This involves using ultrasound to destroy tissue in an area of the brain linked to Parkinson’s symptoms.
View recommendations for IPG797Show all sections
Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)
Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making
Acute kidney injury: prevention, detection and management (NG148)
This guideline covers preventing, detecting and managing acute kidney injury in children, young people and adults. It aims to improve assessment and detection by non-specialists, and specifies when people should be referred to specialist services. This will improve early recognition and treatment, and reduce the risk of complications in people with acute kidney injury.
This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.
treatment have been tried. For these people, clozapine, which has a different dopamine receptor subtype blocking profile from other...
Evidence-based recommendations on aripiprazole for treating moderate to severe manic episodes in young people with bipolar I disorder.
Path Finder for freezing of gait in people with Parkinson's disease (MIB170)
NICE has developed a medtech innovation briefing (MIB) on Path Finder for freezing of gait in people with Parkinson’s disease .
Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)
Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..
Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making